CH₃CH₃
C

CH3CH3

@ch3ch3 · Trace · 0 EXP

Official reference content. Written and reviewed by the site.

joined 8/7/2026

Posts

post in General · 11/21/2026

Cyclazodone: general

Cyclazodone is a synthetic stimulant from the oxazolone family, chemically related to pemoline and thozalinone [1][2]. It was developed by American Cyanamid Company in the 1960s as a central nervous system stimulant and anorectic — something meant to suppress appetite and increase alertness — and was described at the time as useful against fatigue and low mood [3][2]. It was never approved as a medicine anywhere, by the FDA or any other regulator [2][4].

The thing to know before anything else: there is no human data on cyclazodone. Not limited data — none. The only peer-reviewed paper on it is a 1967 note on rats, filed without even an abstract [4]. No human study exists in any retrievable form [4]. Nobody has published dose ranges, onset times, duration, or interaction data in people, and that is not an oversight — it has simply never been studied in humans.

If you use it anyway, that gap is the risk. Start far lower than seems reasonable, use a smaller amount than you'd guess from its relatives, and don't combine it with anything else, stimulant or otherwise, since there is no record of how it behaves in combination. Don't use it alone.

As with amphetamine-type stimulants generally, overdose is a real possibility with substances in this class, and what it looks like depends on the person, the drug, how it's taken, and the dose [5][6]. Excess dopamine and norepinephrine activity is described, in stimulants as a class, as producing heightened alertness, dilated pupils, fast heart rate, high blood pressure, overheating, and seizures, and severe cases can progress to cardiovascular collapse, organ failure, and death [7][8]. Supportive care for stimulant overdose — cooling, sedation, cardiovascular support — is the standard response [6]. None of this has been confirmed in cyclazodone specifically; it is what is known about the class it belongs to, applied to a substance that itself has never been tested in a person.

References

  1. Cyclazodone | C12H12N2O2 | CID 135438121 — PubChem, NIH
  2. Cyclazodone — Wikipedia
  3. US3313688A - Method of producing central nervous system stimulation and anorexia — Google Patents
  4. Cyclazodone: Evidence Ledger — Vialog
  5. Stimulant Guide: Overdose Prevention and Response — Centers for Disease Control and Prevention
  6. SAMHSA Overdose Prevention and Response Toolkit — Substance Abuse and Mental Health Services Administration
  7. Sympathomimetic Toxicity – StatPearls — NCBI Bookshelf
  8. Amphetamine Toxicity – StatPearls — NCBI Bookshelf

post in General · 11/21/2026

Modafiendz: general

Modafiendz is the trade name for N-methyl-4,4-difluoromodafinil [1], a synthetic compound in the modafinil structural series [1] — specifically the bis-fluoro and N-methylated derivative of modafinil, and the N-methyl analogue of flmodafinil and fladrafinil [2]. It is reported as a wakefulness-promoting agent related to modafinil [2], and is sold online and used non-medically as a nootropic [2]. It was never marketed as a pharmaceutical [2].

The one thing to know before anything else: there is no published receptor binding data, no in vivo pharmacology in any species, no pharmacokinetic profile, and no toxicology for Modafiendz specifically [1]. Findings about modafinil itself — dosing, duration, side effects, interactions — do not transfer; they stay bound to the parent compound [1]. The only PubMed record that names this substance is an analytical chemistry paper on thermal degradation of modafinil analogs during gas chromatography, not a safety or efficacy study [3]. Related analogs have turned up identified and quantified in products sold as dietary supplements [3] — not a finding about what a given batch of Modafiendz actually contains, but a reminder that what is in a product and what is on its label are different questions.

That gap means anyone using it is effectively the data. No one can tell you an onset, a duration, or a dose that has been tested in a person. If you are going to use it anyway: start far lower than feels reasonable, do not use it alone, and do not combine it with anything else — not because a specific interaction is known, but because none has been ruled out.

Modafiendz is racemic [4]. It has the molecular formula C16H15F2NO2S [4][5], IUPAC name 2-[Bis(4-fluorophenyl)methanesulfinyl]-N-methylacetamide [5], CAS number 1613222-54-0 [1], and UNII 223VWC34TA [4]. Its molecular weight is reported as both 323.36 [4] and 323.358 [5]. It is also known by the synonyms N-Methyl-4,4-difluoro Modafinil, Dehydroxyfluorafinil, and Methyldifluoromodafinil [4], and reportedly as N-methyl-4,4-difluoromodafinil or N-methylbisfluoromodafinil [2].

References

  1. Modafiendz: Two Structural Edits and a Gas — Kimera Chems
  2. Modafiendz — Wikipedia
  3. Modafiendz | sci-wiki nootropic DB + forum — Scientific Sean · anecdotal report, not evidence
  4. MODAFIENDZ — FDA Global Substance Registration System (GSRS)
  5. Modafiendz | explore | PiHKAL·info — Isomer Design

post in General · 11/21/2026

Fladrafinil: general

Fladrafinil is a wakefulness-promoting agent related to modafinil [1]. It's the bis(4-fluorophenyl) analogue of adrafinil, with a fluorine atom added at the para position of each phenyl ring [2]. Laboratoire L. Lafon patented it in 1984 [2], but it was never brought to market as a medicine [1]. What circulates now is sold online and used non-medically as a nootropic [1].

The main thing to know before anything else: fladrafinil is reported to work as a prodrug for flmodafinil — meaning once it's ingested, your body converts it, and it's flmodafinil's metabolites that turn up afterward [3]. You're not really dosing "fladrafinil" in isolation; you're dosing something that becomes a different, related compound inside you.

The human evidence behind this is thin. The only controlled human data on record comes from a single study in which six volunteers each took 20 mg of either flmodafinil or fladrafinil [3]. That's it — there's no established dosing range, duration, or onset time beyond that one data point, and nothing here should be read as filling that gap. Treat the absence of broader data as the operative fact: start far lower than feels sensible, don't use it alone, and don't combine it with other substances while you're still working out how it affects you.

Fladrafinil is known under several names and codes — CRL-40,941, fluorafinil, bisfluoroadrafinil, and others [4][1][5][2].

References

  1. 2-[[Bis(4-fluorophenyl)methyl]sulfinyl]-N-hydroxyacetamide - Chemical Details — EPA CompTox
  2. Fladrafinil (CRL-40,941): Evidence Ledger — Vialog
  3. Investigations Into the Metabolism and Elimination of Flmodafinil and Fladrafinil for Sports Drug Testing Purposes — Drug Testing and Analysis (Wiley)
  4. Fladrafinil | C15H13F2NO3S | CID 13316557 — PubChem (NIH)
  5. Fladrafinil — Wikipedia

post in General · 11/21/2026

N-Acetyl Semax (amidate): general

N-Acetyl Semax (amidate) is a synthetic derivative of the Russian heptapeptide Semax, modified with an acetyl group [1][2] and an amidated end [3]. Chemically it's defined — Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2, molecular weight 855.0 g/mol, CAS 2920938-90-3 [3] — but that's where the certainty ends.

There is no human safety or pharmacology data on this exact molecule. No peer-reviewed study of the double-capped compound has been found [1], and a PubMed search for "N-acetyl semax" or "NA-Semax-Amidate" returns zero papers [4]. Broader searches under related names (semax amidate, NA-Semax, amidated Semax) also return nothing: no animal experiment, no cell assay, no human observation [5]. The one paper that exists on the exact molecule is a laboratory test-method paper with no biological data [6]. A separate, related search turns up two papers on "N-Acetyl-Semax" (without the amidate), one of which is a binding study [2] — but this is a different, related compound, and no pharmacology, safety, or clinical data for it appear in the retrieved abstracts either [7]. It has no regulatory approval anywhere checked [6][7], no registered clinical trial [4], and the benefits claimed for it online are unpublished [4]. The earliest trace of it existing at all is a 2015 online shop listing [6]. People sometimes describe it as a more stable or stronger version of Semax [2], but that's a claim about the related compound, not evidence about this one, and it's disputed.

What this means in practice: you are not working from a known dose-response curve, known onset, or known interaction profile — because none exists. If you use it anyway, start far lower than seems reasonable, don't use it alone, and don't combine it with anything else. As with nootropics generally, benefits and harms in healthy people are an active area of review, not a settled picture [8].

References

  1. N-Acetyl Semax Amidate - Wikipep — The Peptide Encyclopedia — Wikipep
  2. N-Acetyl-Semax: mechanism, evidence and risks – Synaptik — Synaptik
  3. N-acetyl semax amidate | C39H54N10O10S | CID 172638603 — PubChem, National Library of Medicine
  4. N-Acetyl Semax and N-Acetyl Selank (amidate forms): What the evidence says — Open Peptide Project
  5. The Semax Family · South Beach Longevity — South Beach Longevity
  6. N-Acetyl Semax Amidate: what the studies show, status and safety — myPeptides (harm-reduction resource)
  7. Semax and N Acetyl Semax-Amide: discovery, actions, safety, animal data, and development — HVM Bioflux
  8. Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals (Napoletano, 2022) — East London NHS Foundation Trust

post in General · 11/21/2026

Unifiram: general

Unifiram is a novel cognition enhancer strictly related to piracetam-like compounds [1]. In mice and rats, it ameliorates memory impairment at doses about 1,000 times lower than the most active available nootropic compounds [1], and it blocked amnesia caused by several different disruptions to neurotransmission [2]. In binding studies it showed no affinity for the major central receptors or channels tested, meaning its mechanism isn't explained by the usual targets [2]. Potency comparisons to piracetam are contested: some estimates put it at four orders of magnitude more potent [2], others at around 30,000 times [3]. These are animal-study figures, not evidence about effects or safety in people.

That's the core problem: as of 2015, no formal human studies of unifiram have been conducted [3][4], and there is no human or long-term toxicity data at all [3]. Nothing is known about what doses do in a person, how long effects last, or what happens with repeated use. None of that gap is filled by the animal work above — it answers a different question.

Despite this, unifiram is not patented [3][4] and is commonly sold online [3][4].

The compound has two enantiomers. The (R)-(+)-form is more potent than the (S)-(-)-form, producing comparable effects at roughly 3- to 10-fold lower doses [5].

If you're going to use this anyway: there is no reliable human data to calibrate against, so start far lower than animal-potency comparisons might suggest, don't use alone, and don't combine it with anything else.

Formula: C13H15FN2O3S. FDA UNII: N4024LN29G [6].

References

  1. The novel nootropic compound DM232 (UNIFIRAM) ameliorates memory impairment in mice and rats — University of Florence / Wiley-Liss
  2. Pharmacological Characterization of DM232 (Unifiram) and DM235 (Sunifiram), New Potent Cognition Enhancers — PMC / Wiley
  3. Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings — Taylor & Francis / Journal of Enzyme Inhibition and Medicinal Chemistry
  4. Unifiram — Wikipedia
  5. Enantioselective synthesis and preliminary pharmacological evaluation of the enantiomers of unifiram (DM232), a potent cognition-enhancing agent — PubMed / Wiley
  6. UNII - N4024LN29G — FDA Global Substance Registration System

post in General · 11/21/2026

PPAP (Phenylpropylaminopentane): general

PPAP (phenylpropylaminopentane) is an experimental drug related to selegiline [1], made in Joseph Knoll's Budapest laboratory as a research stimulant [2]. It was made as a version of selegiline with the MAO-B-inhibiting part removed [2], first described in the literature in 1988 and written up in a major paper in 1992 [1], and patented in 1993 as a psychostimulant [3]. It never reached a patient, and its clinical efficacy has never been tested [2]. That matters more than anything else on this page: there is no reliable human data on PPAP. If you use it anyway, that means starting far lower than feels sensible, never using it alone, and never combining it with anything else.

Structurally it's related to the body's own catecholamine transmitters — dopamine, noradrenaline, adrenaline [3]. It's taken up by the catecholamine axon terminal and vesicular membranes [4], and it's reported to act as a potent inhibitor of the uptake of catecholamine transmitters and of the indirect-acting sympathomimetic releasers [4]. It's reported to be devoid of any catecholamine-releasing property of its own [4]. Unlike selegiline, PPAP leaves MAO-B activity unchanged [5], and the (-)-isomer specifically is established as devoid of MAO-B inhibition [6].

PPAP is described as acting as a catecholaminergic activity enhancer, or CAE [1]. How potent a central stimulant this makes it is unsettled: one claim holds it's as potent a stimulant of catecholaminergic neurons as deprenyl [5] (contested), while another holds the (-)-isomer's enhancer activity is more potent than (-)-deprenyl's [6] (contested). Work on PPAP led to the later, improved enhancer compound BPAP in 1999 [1]. Knoll himself described PPAP in 2001 as the first enhancer free of selegiline's unwanted properties [2], a characterization, not a safety finding.

References

  1. Phenylpropylaminopentane — Wikipedia
  2. PPAP · superstack — superstack.wiki
  3. ULB-Article-04_2024-01-PPAP (WM) — Umbrella Labs
  4. The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant — PubMed
  5. Joseph Knoll: Enhancer Sensitive Brain Regulations and Synthetic Enhancers (Selegiline, BPAP) Which Counteract the Regressive Effects of Brain Aging — International Network for the History of Neuropsychopharmacology
  6. Enantioselective synthesis and absolute configuration of (−)-1-(benzofuran-2-yl)-2-propylaminopentane, ((−)-BPAP), a highly potent and selective catecholaminergic activity enhancer — ScienceDirect

post in Legal · 11/19/2026

Fluorophenibut (4-Fluorophenibut): legal

This page summarises the status of fluorophenibut (para-fluorophenibut) in the places checked; it is not legal advice, and it does not cover every country or state.

United States

Fluorophenibut does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[1] Neither does phenibut. That matters for the federal analogue rule, which reaches a substance “the chemical structure of which is substantially similar to the chemical structure of a controlled substance in schedule I or II”:[2] phenibut is in no federal schedule, so it gives fluorophenibut nothing to be an analogue of. No Federal Register document naming fluorophenibut was found on 2026-11-19. Fluorophenibut is not an approved medicine in the United States. Not being federally scheduled is not the same as being legal to sell for consumption.

Connecticut's Schedule I lists “(50) Phenibut”, by name.[3] The regulation covers listed substances “by whatever official, common, usual, chemical, or trade name designation in schedule I”,[3] which means other names for phenibut, not a different compound, and fluorophenibut is not named there.[3] No state schedule naming fluorophenibut was found, and the other states were not checked one by one.

Sport

The World Anti-Doping Agency's list does not name fluorophenibut or phenibut.[4] It states: “This List shall come into effect on 1 January 2026.”[4] Its first class, “S0 NON-APPROVED SUBSTANCES”, is marked “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)” and covers “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”.[4] This page found no approval of fluorophenibut as a medicine anywhere; whether S0 applies to it is a question for an anti-doping authority, not something the list settles by name.

References

  1. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  2. 21 U.S. Code § 802, Definitions (Controlled Substances Act) — Legal Information Institute, Cornell Law School
  3. Regulation concerning Controlled Substance Drug Schedule Updates, RCSA § 21a-243-7 (Schedule I), Wayback capture of 18 June 2026 — Connecticut Department of Consumer Protection, Connecticut eRegulations System
  4. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

Mirogabalin: legal

This page summarises mirogabalin's status in the places checked; it is not legal advice, and it does not cover every country or state.

Japan

On 8 January 2019 Daiichi Sankyo “announced the receipt of marketing approval in Japan” for Tarlige tablets, “generic name: mirogabalin besylate”, “for the treatment of peripheral neuropathic pain”.[1] It is a prescription medicine there.

United States

Mirogabalin is not an approved medicine in the United States, and it does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[2] Its better-known relative pregabalin is in federal Schedule V, listed as “Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid] 2782”.[2] Mirogabalin acts at the same calcium-channel site but is a different compound, so that listing does not cover it. Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.

Sport

The World Anti-Doping Agency's list, which states “This List shall come into effect on 1 January 2026.”, does not name mirogabalin.[3]

References

  1. Daiichi Sankyo Announces Marketing Approval in Japan of 'Tarlige Tablets' for Pain Treatment (press release, 8 January 2019) — Daiichi Sankyo Company, Limited
  2. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  3. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

N-Acetyl Semax (amidate): legal

This page summarises the status of N-acetyl semax (sold as N-acetyl semax amidate) in the places checked; it is not legal advice, and it does not cover every country or state.

United States

N-acetyl semax does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[1] It is not an approved medicine in the United States. Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.

The 2026 HHS policy on compounding peptides does not reach it either. That policy describes Semax by its sequence: “its AA sequence is H-Met-Glu-His-Phe-Pro-Gly-Pro-OH”.[2] N-acetyl semax amidate carries an acetyl group on one end and an amide on the other, so it is a different molecule. Even for Semax, the policy says “enforcement discretion for Semax free base is appropriate for intranasal use”, and only for pharmacy compounding under its conditions.[2]

Sport

The World Anti-Doping Agency's list does not name N-acetyl semax or Semax.[3] It states: “This List shall come into effect on 1 January 2026.”[3] Its first class, “S0 NON-APPROVED SUBSTANCES”, is marked “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)” and covers “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”.[3] This page found no approval of the N-acetyl amidate form as a medicine; whether S0 applies to it is a question for an anti-doping authority, not something the list settles by name.

References

  1. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  2. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (Wayback capture of 15 November 2026) — US Department of Health and Human Services
  3. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

Memantine: legal

This page summarises memantine's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

Memantine is an approved prescription medicine. The FDA records that Namenda tablets “are the subject of NDA 021487 held by AbbVie Inc. and initially approved on October 16, 2003”, and that “Namenda is indicated for the treatment of moderate to severe dementia of the Alzheimer's type”.[1] The brand tablets are now discontinued; in September 2026 the FDA determined they “were not withdrawn from sale for reasons of safety or effectiveness”, which lets generic versions keep being approved.[1] Use for memory or tolerance outside that indication is off-label, and the drug still needs a prescription.

Memantine does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[2] State law was not checked for this page.

Sport

The World Anti-Doping Agency's list, which states “This List shall come into effect on 1 January 2026.”, does not name memantine.[3]

References

  1. Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (FR Doc. 2026-17812, 1 September 2026) — Food and Drug Administration, Federal Register
  2. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  3. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

JJC8-088: legal

This page summarises this compound's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

JJC8-088 does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19; “Modafinil”, the drug its design started from, does, in Schedule IV.[1] The federal Analogue Act does not reach JJC8-088 through modafinil: it covers a substance “the chemical structure of which is substantially similar to the chemical structure of a controlled substance in schedule I or II”, and modafinil is in Schedule IV.[2] It is a research compound, not an approved medicine in the United States. Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.

Sport

The World Anti-Doping Agency's list does not name JJC8-088.[3] It states: “This List shall come into effect on 1 January 2026.”[3] It names “Modafinil” in its “S6 STIMULANTS” class, marked “PROHIBITED IN-COMPETITION”, which adds: “A stimulant not expressly listed in this section is a Specified Substance.”[3] Whether this compound is treated as one is a question for an anti-doping authority, not something the list settles by name.

References

  1. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  2. 21 U.S. Code § 802, Definitions (paragraph 32, controlled substance analogue) — Legal Information Institute, Cornell Law School
  3. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

PRE-084: legal

This page summarises this compound's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

PRE-084 does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[1] It is not an approved medicine in the United States. Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.

Sport

The World Anti-Doping Agency's list does not name PRE-084.[2] It states: “This List shall come into effect on 1 January 2026.”[2] Its first class, “S0 NON-APPROVED SUBSTANCES”, is marked “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)” and covers “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”.[2] The compound is not an approved medicine in the United States; whether S0 applies to it is a question for an anti-doping authority, not something the list settles by name.

References

  1. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  2. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

9-Me-BC (9-Methyl-beta-carboline): legal

This page summarises this compound's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

9-Me-BC does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[1] It is not an approved medicine in the United States. Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.

Sport

The World Anti-Doping Agency's list does not name 9-Me-BC.[2] It states: “This List shall come into effect on 1 January 2026.”[2] Its first class, “S0 NON-APPROVED SUBSTANCES”, is marked “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)” and covers “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”.[2] The compound is not an approved medicine in the United States; whether S0 applies to it is a question for an anti-doping authority, not something the list settles by name.

References

  1. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  2. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

Unifiram: legal

This page summarises unifiram's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

Unifiram does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[1] It is not an approved medicine in the United States. Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.

Sport

The World Anti-Doping Agency's list does not name unifiram.[2] It states: “This List shall come into effect on 1 January 2026.”[2] Its first class, “S0 NON-APPROVED SUBSTANCES”, is marked “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)” and covers “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”.[2] The compound is not an approved medicine in the United States; whether S0 applies to it is a question for an anti-doping authority, not something the list settles by name.

References

  1. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  2. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

Sunifiram: legal

This page summarises sunifiram's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

Sunifiram does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[1] It is not an approved medicine in the United States. Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.

Sport

The World Anti-Doping Agency's list does not name sunifiram.[2] It states: “This List shall come into effect on 1 January 2026.”[2] Its first class, “S0 NON-APPROVED SUBSTANCES”, is marked “PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)” and covers “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”.[2] The compound is not an approved medicine in the United States; whether S0 applies to it is a question for an anti-doping authority, not something the list settles by name.

References

  1. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  2. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

Amantadine: legal

This page summarises amantadine's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

Amantadine is an approved medicine. A current generic label reads: “Amantadine hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus” and “Amantadine hydrochloride tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions”.[1] An extended-release brand, Gocovri, is labelled “For the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy”.[2]

It does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.[3] State law was not checked for this page.

Sport

The World Anti-Doping Agency's list, which states “This List shall come into effect on 1 January 2026.”, does not name amantadine.[4]

References

  1. Amantadine hydrochloride tablets, US prescribing information (ANDA076186), DailyMed, read 2026-11-19 — US National Library of Medicine (DailyMed), label as submitted to the FDA
  2. Gocovri (amantadine) extended-release capsules, US prescribing information, via openFDA drug labels, read 2026-11-19 — US Food and Drug Administration (openFDA)
  3. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  4. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

Desoxypipradrol (2-DPMP): legal

This page summarises desoxypipradrol's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

Desoxypipradrol does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19; its parent, “Pipradrol”, does, in Schedule IV.[1] The federal Analogue Act does not reach desoxypipradrol through pipradrol: it covers a substance “the chemical structure of which is substantially similar to the chemical structure of a controlled substance in schedule I or II”, and pipradrol is in Schedule IV.[2] Desoxypipradrol is not an approved medicine in the United States. Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.

United Kingdom

The Misuse of Drugs Act 1971 (Amendment) Order 2012, made on 2012-05-30, states: “This Order adds, in article 2, Desoxypipradrol” to the part of the Act “which specifies the drugs which are subject to control under that Act as Class B drugs”.[3] The control is generic, covering “Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group”, and the order says it “shall come into force on the fourteenth day after the day on which it is made”.[3]

Sport

The World Anti-Doping Agency's list, which states “This List shall come into effect on 1 January 2026.”, does not name desoxypipradrol. Its stimulants class, marked “PROHIBITED IN-COMPETITION”, adds: “A stimulant not expressly listed in this section is a Specified Substance.”[4] Whether desoxypipradrol is treated as one is a question for an anti-doping authority, not something the list settles by name.

References

  1. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  2. 21 U.S. Code § 802, Definitions (paragraph 32, controlled substance analogue) — Legal Information Institute, Cornell Law School
  3. The Misuse of Drugs Act 1971 (Amendment) Order 2012, SI 2012/1390, as made — UK Government, via legislation.gov.uk (The National Archives)
  4. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

Pipradrol: legal

This page summarises pipradrol's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

Pipradrol is a federal Schedule IV controlled substance: the schedule lists “Pipradrol 1750”.[1] It is not an approved medicine in the United States, and state law was not checked for this page.

United Kingdom

Pipradrol is a Class C drug in the UK: the Misuse of Drugs Act 1971 (Amendment) Order 2012 moved it within the part of the Act “which specifies the drugs which are subject to control under that Act as Class C drugs”, rather than out of it.[2] The same order put its relatives, including desoxypipradrol, in Class B through a generic definition that begins “Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group”.[2]

Sport

The World Anti-Doping Agency's list, which states “This List shall come into effect on 1 January 2026.”, names “pipradrol” in a footnote to its stimulants class: “These substances are included in the 2026 Monitoring Program and are not considered Prohibited Substances.”[3] Monitored means testing laboratories report it so WADA can watch for misuse; it is not a violation.

References

  1. 21 CFR 1308.14, Schedule IV (eCFR, current as read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  2. The Misuse of Drugs Act 1971 (Amendment) Order 2012, SI 2012/1390, as made — UK Government, via legislation.gov.uk (The National Archives)
  3. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

Pemoline: legal

This page summarises pemoline's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

Pemoline is a federal Schedule IV controlled substance: the schedule lists “Pemoline (including organometallic complexes and chelates thereof) 1530”.[1]

It was sold as a prescription stimulant under the name Cylert until 2005, when the FDA concluded that “the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug”.[2] Its analogues sold as nootropics, such as cyclazodone and fenozolone, are not named in the federal schedules, and state law was not checked for this page.

Sport

The World Anti-Doping Agency's list, which states “This List shall come into effect on 1 January 2026.”, names “Pemoline” among the “S6.B: SPECIFIED STIMULANTS”, a class marked “PROHIBITED IN-COMPETITION”.[3]

References

  1. 21 CFR 1308.14, Schedule IV (eCFR, current as read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  2. Information for Healthcare Professionals: Pemoline Tablets and Chewable Tablets (marketed as Cylert), FDA Alert 10/2005, Wayback capture of 3 December 2017 — US Food and Drug Administration
  3. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

post in Legal · 11/19/2026

PPAP (Phenylpropylaminopentane): legal

This page summarises PPAP's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

PPAP, “1-phenyl-N-propylpentan-2-amine” in PubChem's naming, is an amphetamine relative: a phenethylamine with a propyl group on the carbon next to the nitrogen and another propyl group on the nitrogen.[1] It does not appear by name in the federal controlled-substance schedules, read on 2026-11-19. Its best-known relatives do: Schedule II lists “Amphetamine, its salts, optical isomers, and salts of its optical isomers 1100” and “Methamphetamine, its salts, isomers, and salts of its isomers 1105”.[2] Whether federal analogue law reaches PPAP was not assessed for this page. Not being federally scheduled is not the same as being legal to sell for consumption.

States

Three state schedules were read on 2026-11-19, and none names PPAP.

Florida's statute is the one whose words may reach it. Under “The following substances are controlled in Schedule I”, among the “hallucinogenic substances”, it has a class titled “Substituted Phenethylamines”.[3] The class covers “any compound containing a phenethylamine structure, without a beta-keto group, and without a benzyl group attached to the amine group”, and it allows a compound “with or without substitution at the alpha or beta position by any alkyl substituent, with or without substitution at the nitrogen atom”.[3] PPAP's structure matches each of those words: its extra groups are an alkyl (propyl) group on the alpha carbon and an alkyl (propyl) group on the nitrogen, it has no beta-keto group, and its nitrogen carries no benzyl group.[1] No official determination, ruling or prosecution naming PPAP was found, so whether the class covers it is a reading of the statute's text, not a listing.

Texas puts “Methamphetamine, including its salts, optical isomers, and salts of optical isomers” in its “PENALTY GROUP 1”, and PPAP is not named anywhere in the chapter.[4] Virginia's Schedule II covers “any substance which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers”, and none of its schedules names PPAP.[5] Other states, and the states' analogue provisions, were not checked for this page.

Sport

The World Anti-Doping Agency's list, which states “This List shall come into effect on 1 January 2026.”, does not name PPAP. Under “S6.B: SPECIFIED STIMULANTS” it lists “Phenethylamine and its derivatives”, in a class marked “PROHIBITED IN-COMPETITION”.[6] As with Florida, that PPAP falls under the entry is a reading of its words; no anti-doping ruling on PPAP was looked for.

References

  1. PubChem CID 10262369 (PPAP): IUPAC name and formula — PubChem, US National Library of Medicine
  2. 21 CFR 1308.12, Schedule II (eCFR, current as read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  3. Florida Statutes § 893.03, Standards and schedules (2026 Florida Statutes, read 2026-11-19) — Florida Legislature (Online Sunshine)
  4. Texas Health and Safety Code chapter 481, Texas Controlled Substances Act (§ 481.102, Penalty Group 1; read 2026-11-19) — Texas Legislature (Texas Legislative Council)
  5. Code of Virginia § 54.1-3448, Schedule II (read 2026-11-19) — Virginia General Assembly, Legislative Information System
  6. World Anti-Doping Code International Standard: Prohibited List 2026, Wayback capture of 19 November 2026 — World Anti-Doping Agency

Comments

No public comments yet.

Tell us something